Screening methods in the detection of bladder cancer: Comparison of nuclear matrix protein-22, bladder tumor antigen
and cytological examinations [in Japanese].
Among them, bladder tumor antigen
(BTA) in urine is a sensitive marker and has been used as an adjunct to cystoscopy in the diagnosis and follow-up of patients with BC (6-10).
To meet these criteria, substantial research has focused on developing a variety of potential biomarkers, including nuclear matrix protein, fibrin/fibrinogen product, bladder tumor antigen
, telomeric repeat amplification protocols (TRAP), tumor-associated antigens, hyaluronic acid, and hyaluronidase.
Tumor markers used in this study were the nuclear matrix protein (Matritech NMP-22) and the bladder tumor antigen
(Bard BTA), which are commercially available, and the telomerase assay (TRAP) which is currently under investigation.
Recent reports have described the application of urine-based markers, including bladder tumor antigen
(BTA),6 nuclear matrix protein-22 (NMP22), and the urinary bladder cancer (UBC) test (5, 6).